Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal...
December 14 2017 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based,
nutraceutical company devoted to improving the way people age,
announced important cardiac research by Dr. Mathias Mericksay and
colleagues at the l’Université Paris-Sud, and Dr. Charles Brenner
and colleagues at the University of Iowa, published in the journal
Circulation. This research revealed that in a mouse model of
heart failure, a loss of NAD levels is accompanied by activation of
the nicotinamide riboside (NR) kinase pathway; administration of
NIAGEN® in this model stabilizes NAD levels and leads to protective
effects on cardiac function that may someday lead to a new
therapeutic option for heart failure patients.
With heart failure in the United States alone
affecting about 5.7 million adults and costing an estimated $30.7
billion each year, identifying mechanisms of failures in heart
bioenergetics and identifying protective and therapeutic approaches
is one of the highest biomedical priorities in the developed world.
In this new research, Drs. Mericksay, Brenner and colleagues
discovered that in heart failure, activation of the NR kinase
pathway, which occurs as a result of energy stress and NAD
depletion is common to humans and mice. Because of activation
of the NR kinase pathway, NR restores but nicotinamide fails to
restore NAD levels. Measures of cardiac function are improved with
oral administration of NR in this mouse model of heart failure.
Frank Jaksch, CEO of ChromaDex, concluded that,
“It is very exciting to see research from our collaborative study
program, leading to peer reviewed publications in top tiered
journals, that expands our knowledge of the potential therapeutic
indications for NR.”
Because the depression in NAD and the activation
of the NR kinase pathway are common between humans and mice, the
research strongly suggests that NIAGEN® may be capable of
protecting against human heart failure. Nicotinamide riboside,
discovered as a vitamin by Dr. Charles Brenner, is a
patent-protected molecule that was developed and commercialized by
ChromaDex as NIAGEN®. NIAGEN® is produced under Good
Manufacturing Practices (GMP) and has New Dietary Ingredient
Notification (NDIN) filed with the US Food and Drug Administration
without comment.
Remarking on Dr. Mericksay and Brenner’s
discovery, Dr. Roger Kornberg, the Winzer Professor in Medicine at
Stanford University, 2006 Nobel Prize Winner in Chemistry and Chair
of the ChromaDex Scientific Advisory Board, stated, “This is but
another remarkable discovery about the unique value of NIAGEN® in
maintaining NAD-dependent functions not only in health but also in
disease states.”
Robert N. Fried, President and Chief Strategy
Officer of ChromaDex added, “This is a highly valuable contribution
from the most powerful global team of NAD scientists, who include
Dr. Charles Brenner, our Chief Scientific Advisor, Dr. Mathias
Mericksay, a renowned molecular cardiologist, and others. The
combination of Dr. Brenner’s metabolomic technologies with gene
expression profiling tell us exactly which diseases have NAD
deficits accompanied by induction of the NR pathway.”
To learn more about ChromaDex, please
visit www.ChromaDex.com.
About ChromaDex:
ChromaDex Corp. is an integrated, global
nutraceutical company devoted to improving the way people age.
ChromaDex scientists partner with leading universities and research
institutions worldwide to uncover the full potential of NAD and
identify and develop novel, science-based ingredients. Its
flagship ingredient, NIAGEN® nicotinamide riboside, sold directly
to consumers as TRU NIAGEN™, is backed with clinical and scientific
research, as well as extensive IP protection. TRU NIAGEN™ is
helping the world AGE BETTER®. To learn more about ChromaDex,
please visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended including statements related to results of the study and
its significance related to NAD as an effective precursor to
protect cardiac function in an animal model of heart failure and
that the new research suggests that the protective benefits of NR
may lead to a new therapeutic option in human heart failure.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. Actual results may differ materially from those set
forth in this release due to the risks and uncertainties inherent
in ChromaDex's business. More detailed information about ChromaDex
and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2016,
ChromaDex's Quarter Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Investor Relations Contact: Andrew
Johnson, Director of Investor Relations 949-419-0288
andrewj@chromadex.com
ChromaDex Public Relations Contact: Breah
Ostendorf, Director of Marketing 949-537-4103
breaho@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024